The BrightEdge Fund 2021 Annual Review
November 01, 2022
An innovation showcase of protein degraders, RNA therapeutics, delivery vectors and gene modifiers
Media Coverage
Interius Named as Finalist for the Deal of the Year Award by Life Sciences Pennsylvania
November 01, 2022
An innovation showcase of protein degraders, RNA therapeutics, delivery vectors and gene modifiers
BioCentury’s 2021 Class of Emerging Companies
February 14, 2022
An innovation showcase of protein degraders, RNA therapeutics, delivery vectors and gene modifiers
Penn Cell and Gene Therapy Spinout Interius Biotherapeutics Raises $76 Million
May 18, 2021